Burden of Asthma and Role of 2.5 µg Tiotropium Respimat® as an Add-On Therapy: A Systematic Review of Phase 2/3 Trials.

abstract：:Many doubts surround the numerous forms of nonsurgical treatment of nonresectable hepatocellular carcinoma (HCC). Our study aimed to reach reliable conclusions on the actual efficacy of these treatments. We examined 85 studies involving a total of 6746 patients: 6113 were treated; the remaining 633 were not. We applie...

journal_title：Advances in therapy

authors： Malaguarnera M,Trovato G,Restuccia S,Giugno I,Franzé CM,Receputo G,Siciliano R,Motta M,Trovato BA

更新日期：1994-11-01 00:00:00

abstract：INTRODUCTION:Phase IV post-marketing surveillance studies are needed to evaluate the real-world safety and effectiveness of drug products. This study aimed to evaluate the safety and effectiveness of biosimilar etanercept (Altebrel, AryoGen Co., Iran) in patients with rheumatoid arthritis (RA), ankylosing spondylitis (...

journal_title：Advances in therapy

authors： Gharibdoost F,Salari AH,Salesi M,Ebrahimi Chaharom F,Mottaghi P,Hosseini M,Sahebari M,Nazarinia M,Mirfeizi Z,Shakibi M,Moussavi H,Karimifar M,Mowla K,Karimzadeh H,Anjidani N,Jamshidi A

更新日期：2021-01-11 00:00:00

abstract：INTRODUCTION:Antipsychotic medications are associated with significant weight gain, type 2 diabetes mellitus, dyslipidemia, and increased cardiovascular risk. Suggested mechanisms of weight gain from antipsychotic medication include antagonism of histamine and serotonin receptors, and effects on the hypothalamic-pituit...

journal_title：Advances in therapy

authors： Gross C,Blasey CM,Roe RL,Allen K,Block TS,Belanoff JK

更新日期：2009-10-01 00:00:00

abstract：INTRODUCTION:Aripiprazole and olanzapine are atypical antipsychotics. Both drugs can induce metabolic changes; however, the metabolic side effects produced by aripiprazole are more benign. The aim of the study was to evaluate if aripiprazole and olanzapine alter prolactin levels, lipid and glucose metabolism and hepati...

journal_title：Advances in therapy

authors： Koller D,Almenara S,Mejía G,Saiz-Rodríguez M,Zubiaur P,Román M,Ochoa D,Navares-Gómez M,Santos-Molina E,Pintos-Sánchez E,Abad-Santos F

更新日期：2020-12-05 00:00:00

abstract：OBJECTIVE:Examine outcomes and costs of patients with persistent asthma who initiated treatment with beclomethasone dipropionate hydrofluoroalkane (BDP-HFA) or fluticasone propionate (FP). METHODS:MedStat's Commercial Claims and Encounters database (July 1, 2002-June 30, 2007) was utilized. Patients (n=13,968) were in...

journal_title：Advances in therapy

authors： Lage MJ,Gross GN,Brewster C,Spalitto A

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:The 21-gene breast cancer assay (Oncotype DX(®); Genomic Health, Inc.) is a validated diagnostic test that predicts the likelihood of adjuvant chemotherapy benefit and 10-year risk of distant recurrence in patients with hormone-receptor-positive, human epidermal growth receptor 2-negative, early-stage brea...

journal_title：Advances in therapy

authors： Bargalló-Rocha JE,Lara-Medina F,Pérez-Sánchez V,Vázquez-Romo R,Villarreal-Garza C,Martínez-Said H,Shaw-Dulin RJ,Mohar-Betancourt A,Hunt B,Plun-Favreau J,Valentine WJ

更新日期：2015-03-01 00:00:00

abstract：:The origin of chronic periodontal disease is strongly related to the nature and physiology of the subgingival bacterial biofilm, of which Porphyromonas gingivalis is a main protagonist. This study was conducted in vitro, to test the susceptibility of the W83 strain of P gingivalis to several oral antiseptics, bearing ...

journal_title：Advances in therapy

authors： Bercy P,Lasserre J

更新日期：2007-11-01 00:00:00

abstract：INTRODUCTION:Pulmonary arterial hypertension (PAH) is associated with poor prognosis despite significant recent advances in its treatment. An intravenous formulation of epoprostenol sodium containing glycine and mannitol (epoprostenol GM; GlaxoSmithKline, London, UK) is widely used to treat PAH. A new formulation of ep...

journal_title：Advances in therapy

authors： Tamura Y,Ono T,Fukuda K,Satoh T,Sasayama S

更新日期：2013-05-01 00:00:00

abstract：:This interventional study was undertaken to assess the impact of physiotherapy education on the knowledge and attitudes of physiotherapists (PTs) and physiotherapy students (PSs) toward euthanasia. The study, which was conducted during the period between 2004 and 2005, included a total of 494 participants (311 PTs; 18...

journal_title：Advances in therapy

authors： Cavlak U,Aslan UB,Gurso S,Yagci N,Yeldan I

更新日期：2007-01-01 00:00:00

abstract：INTRODUCTION:Pigmented villonodular synovitis (PVNS), also known as giant-cell tumour of the tendon sheath (GCTT), is a rare, benign proliferative tumour affecting the inner lining of synovial joints and tendon sheets. Information on treatment needs of PVNS patients to inform drug development is currently scarce. We co...

journal_title：Advances in therapy

authors： Cook NS,Landskroner K,Shah B,Walda S,Weiss O,Pallapotu V

更新日期：2020-06-01 00:00:00

abstract：INTRODUCTION:Real-world data are sparse on longitudinal associations of opioid use with pain interference with activities (PIA) and daily function with osteoarthritis (OA) in the USA. METHODS:Data from the 2010-2015 Medical Expenditure Panel Surveys were analyzed for community-dwelling adults with OA. Opioid use patte...

journal_title：Advances in therapy

authors： Shah D,Zhao X,Wei W,Gandhi K,Dwibedi N,Webster L,Sambamoorthi U

更新日期：2020-02-01 00:00:00

abstract：:Permixon, the lipidosterolic extract of Serenoa repens, is widely used for the treatment of symptoms associated with benign prostatic hyperplasia (BPH). This open study assessed the efficacy and tolerability of Permixon 160 mg twice daily administered for 2 years. One hundred fifty-five men with clinically diagnosed B...

journal_title：Advances in therapy

authors： Pytel YA,Vinarov A,Lopatkin N,Sivkov A,Gorilovsky L,Raynaud JP

更新日期：2002-11-01 00:00:00

abstract：INTRODUCTION:Alcohol dependence represents a severe pathological disorder associated with a significant rate of morbidity and mortality. To date, limited pharmacological agents exist to treat this disorder, and there is a growing interest for new therapies. In this context, pregabalin represents a promising strategy. P...

journal_title：Advances in therapy

authors： Guglielmo R,Martinotti G,Clerici M,Janiri L

更新日期：2012-11-01 00:00:00

abstract：INTRODUCTION:The traditional model of evaluating treatments based primarily on primary outcome measures has stumbled in its application to rare disease. Rare disease clinical trials face the methodological challenges of small, heterogeneous patient populations and relatively few validated, disease-specific outcome meas...

journal_title：Advances in therapy

authors： Contesse MG,Valentine JE,Wall TE,Leffler MG

更新日期：2019-05-01 00:00:00

abstract：INTRODUCTION:To evaluate the retinal function and the relative neural conduction along the visual pathway after treatment with citicoline in liposomal formulation (CLF) eye drops in patients with open angle glaucoma (OAG). METHODS:Twelve OAG patients (mean age ± standard deviation 52.58 ± 11.39 years, intraocular pres...

journal_title：Advances in therapy

authors： Parisi V,Oddone F,Roberti G,Tanga L,Carnevale C,Ziccardi L,Manni G

更新日期：2019-04-01 00:00:00

abstract：INTRODUCTION:Data regarding the prevalence of immune thrombocytopenia (ITP) is limited, and is derived from North American population-based analyses. Therefore, the authors conducted the first study outside the United States (US) using the United Kingdom (UK) General Practice Research Database (GPRD) to estimate the ad...

journal_title：Advances in therapy

authors： Bennett D,Hodgson ME,Shukla A,Logie JW

更新日期：2011-12-01 00:00:00

abstract：INTRODUCTION:Intanza® 9 μg (Sanofi Pasteur SA, Lyon, France), a split virion trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available as a vaccination for adults aged 18 to 59 years old, as of the 2010 southern hemisphere influenza season. METHODS:This study was des...

journal_title：Advances in therapy

authors： Eizenberg P,Booy R,Naser N,Mason G,Stamboulian D,Weber F

更新日期：2011-08-01 00:00:00

abstract：:In a randomized, controlled, double-blind trial, 70 patients (mean age, 49.7 years) suffering from mild to moderate depression received one tablet of either St. John's Wort (Hypericum perforatum) extract (Calmigen) or fluoxetine hydrochloride (Prozac) twice a day for 6 weeks. Efficacy was determined according to the 1...

journal_title：Advances in therapy

authors： Behnke K,Jensen GS,Graubaum HJ,Gruenwald J

更新日期：2002-01-01 00:00:00

abstract：:The extensive use of angiotensin-converting enzyme inhibitors (ACEIs) as antihypertensive agents and the huge amount of data collected in clinical trials and post-marketing studies has allowed the extending of the indication of ACEIs beyond blood pressure control. Current guidelines recommend ACEIs in symptomatic pati...

journal_title：Advances in therapy

authors： Borghi C,Omboni S

更新日期：2020-10-01 00:00:00

abstract：:Alpha-mannosidosis is a rare lysosomal storage disorder that generally presents in early childhood. It is a progressive, highly heterogeneous disease that is difficult to recognize, and a diagnosis is usually reached after referrals to multiple specialists. It is important to understand the challenges faced by patient...

journal_title：Advances in therapy

authors： Verrecchia E,Sicignano LL,Massaro MG,Rocco R,Silvestri G,Rossi S,Manna R

更新日期：2020-11-24 00:00:00

abstract：INTRODUCTION:New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Hodgkin's lymphoma, and...

journal_title：Advances in therapy

authors： Gulácsi L,Brodszky V,Baji P,Rencz F,Péntek M

更新日期：2017-05-01 00:00:00

abstract：INTRODUCTION:Our objective was to determine the effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in a broad range of patient profiles, including subgroups with varying hypertension severity, age and cardiovascular risk profiles. METHODS:Patient data from four large prospective observat...

journal_title：Advances in therapy

authors： Dézsi CA,Glezer M,Karpov Y,Brzozowska-Villatte R,Farsang C

更新日期：2020-11-05 00:00:00

abstract：INTRODUCTION:Extraintestinal manifestations (EIMs) in patients with Crohn's disease (CD) are common and associated with additional morbidity. This study aimed to evaluate the effect of adalimumab therapy on EIM resolution and identify potential predictors of EIM resolution in adult and pediatric patients with moderate ...

journal_title：Advances in therapy

authors： Louis EJ,Reinisch W,Schwartz DA,Löfberg R,Robinson AM,Berg S,Wang AW,Maa JF,Huang B,Pappalardo B

更新日期：2018-04-01 00:00:00

abstract：:Convergent evidence indicates that abnormalities in the innate immune system may be pertinent to the pathogenesis, phenomenology, and possible treatment of several mental disorders. In keeping with this view, the targeting of interleukin-6 with the human monoclonal antibody sirukumab may represent a possible treatment...

journal_title：Advances in therapy

authors： Zhou AJ,Lee Y,Salvadore G,Hsu B,Fonseka TM,Kennedy SH,McIntyre RS

更新日期：2017-01-01 00:00:00

abstract：INTRODUCTION:Patients with chronic kidney disease (CKD) have an increased risk of comorbid conditions, including cardiovascular disease (CVD). Anemia is prevalent in the CKD population and worsens as kidney function declines, resulting in a diminished quality of life and increased morbidity/mortality. The purpose of th...

journal_title：Advances in therapy

authors： Covic A,Jackson J,Hadfield A,Pike J,Siriopol D

更新日期：2017-07-01 00:00:00

abstract：:Cardiovascular diseases (CVDs) are the leading cause of premature deaths globally and in Ukraine. Dyslipidemia is a recognized risk factor for the development of CVD. Therefore, early detection and appropriate management of dyslipidemia are essential for the primary prevention of CVDs. However, currently, there is a l...

journal_title：Advances in therapy

authors： Dolzhenko MM,Barnett OY,Grassos C,Dragomiretska NV,Goloborodko BI,Ilashchuk TO,Zuiev KO,Karpenko OV,Kolesnikova OV,Kolesnyk TV,Talaieva TV,Vakaliuk IP,Tiabut TD,Mesnikova IL,Zinych OV

更新日期：2020-11-01 00:00:00

abstract：INTRODUCTION:Asthma is associated with significant economic burden. Inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) combination therapies are considered mainstays of treatment. We describe real-world use of ICS/LABAs by comparing treatment persistence and adherence among patients with asthma in the Unit...

journal_title：Advances in therapy

authors： Parimi M,Svedsater H,Ann Q,Gokhale M,Gray CM,Hinds D,Nixon M,Boxall N

更新日期：2020-06-01 00:00:00

abstract：:The present study, which was designed as a prospective, double-masked, randomized, controlled, single-site study, was conducted to compare the effects of 3 approved ophthalmic nonsteroidal anti-inflammatory drugs-nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc., Fort Worth, Tex), ketorolac trome...

journal_title：Advances in therapy

authors： Durrie DS,Kennard MG,Boghossian AJ

更新日期：2007-11-01 00:00:00

abstract：INTRODUCTION:In budesonide/formoterol (Symbicort(R) Turbuhaler(R), AstraZeneca, Lund, Sweden) maintenance and reliever therapy (SMART), patients with asthma take a daily maintenance dose of budesonide/formoterol, with the option of taking additional doses for symptom relief instead of a short-acting beta(2)-agonist (SA...

journal_title：Advances in therapy

authors： Goossens LM,Riemersma RA,Postma DS,van der Molen T,Rutten-van Mölken MP

更新日期：2009-09-01 00:00:00

abstract：:In this 2-week, randomized, crossover study, ophthalmic solutions of nedocromil sodium 2% and olopatadine hydrochloride 0.1% were compared for effectiveness and acceptability in 28 patients with perennial allergic conjunctivitis and previous olopatadine experience. Patients received nedocromil twice daily or olopatadi...

journal_title：Advances in therapy

authors： Alexander M,Allegro S,Hicks A

更新日期：2000-05-01 00:00:00